Clinical trials: Anticoagulant Drugs
Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
Phase I Study of MT1011 Injection in Healthy Subjects
This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects.
- Trial name
- NCT07024160
- Testing
- MT1011
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Venous Thromboembolism, Bleeding
Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial
Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS) trial is a pragmatic, international, multicenter, randomized controlled open label trial comparing a direct oral anticoagulant (DOAC) - oral factor Xa inhibitor apixaban…
- Trial name
- ARTS (NCT06523959)
- Testing
- Apixaban 2.5 MG
- Where
- Finland
- Volunteers
- 5,436 people
- Sponsor
- Clinical Urology and Epidemiology Working Group
Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB)
FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)
Background Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended for stroke prevention in non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper), Drug-Related Side Effects and Adverse Reactions
- Trial name
- FENOX (NCT07497893)
- Testing
- Fexuprazan, NOAC therapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Anticoagulants, Platelet Aggregation Inhibitors
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
The study will assess the hypothesis that the combination warfarin \& clopidogrel 75 mg/day is superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect to bleeding complications while equally…
- Conditions
- Anticoagulants, Platelet Aggregation Inhibitors, Stents, Atrial Fibrillation
- Trial name
- WOEST (NCT00769938)
- Testing
- PCI (percutaneous coronary intervention)
- Where
- 15 sites in Belgium, Netherlands
- Volunteers
- 573 people, healthy volunteers welcome
- Sponsor
- R&D Cardiologie
Coronary Artery Disease
Canadian Anticoagulant Percutaneous Coronary Intervention Registry
Advances in mechanical intervention (PCI) and anticoagulation therapy have been the cornerstone of treatment of patients with coronary artery disease.
- Trial name
- CAPCIR (NCT00773006)
- Where
- Canada
- Volunteers
- 747 people
- Sponsor
- University of Alberta
Heart Disease, Stroke
Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is better for preventing death and stroke in patients with poor heart function.
- Conditions
- Heart Disease, Stroke, Ischemic Heart Disease, Myocardial Infarction
- Trial name
- WARCEF (NCT00041938)
- Testing
- aspirin, Warfarin
- Where
- 64 sites in United States, Canada
- Volunteers
- 2,305 people
- Sponsor
- Columbia University
Bleeding, End Stage Renal Disease
Pilot Bleeding Study: Risk and Protective Factors Associated With Bleeding in the Hemodialysis Population
This study is examining the risk and protective factors associated with bleeding in the hemodialysis population.
- Trial name
- NCT00182117
- Where
- Canada
- Volunteers
- 490 people
- Sponsor
- Hamilton Health Sciences Corporation
Subject Under Anticoagulant
Prospective Real-world Registry Describing Treatment Regimens
This study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
- Trial name
- PRAETORIAN (NCT03942913)
- Testing
- an observational study
- Where
- France
- Volunteers
- 573 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Assessment of Activity of Anti-Xa Factor in Patients Treated With Continuous Veno-venous Hemodiafiltration Receiving Anticoagulant Prophylaxis
Impact of Continuous Veno-venous Hemodiafiltration on Efficacy of Administration of Prophylactic Doses of Enoxaparin or Fondaparinux in Critically Ill Patients.
Dose of anticoagulant prophylaxis in patients with continuous veno-venous hemodiafiltration may be insufficient to keep anti-Xa factor activity in prophylactic range.
- Trial name
- NCT04671160
- Testing
- Assessment the activity of anti-Xa factor.
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Medical University of Gdansk
Anticoagulants and Bleeding Disorders
MAC Project, Monitoring of AntiCoagulant Therapies (MAC)
MAC Project is a prospective cohort, multicenter, observational, no-profit study aimed to prospectively collect reliable real-life clinical information in unselected VTE or NVAF patients treated with any DOAC, during a…
- Trial name
- MAC (NCT04329390)
- Testing
- Anticoagulant drugs
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Quovadis Associazione
Hypertriglyceridemia
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
The primary objective of this study is to determine the effect of Epanova® on the pharmacokinetic and anticoagulant activity of warfarin.
- Trial name
- NCT01431690
- Testing
- warfarin, omefas, omega-3-acid ethyl esters
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Atrial Fibrillation, Atrial Flutter
Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation
The overall goal of this study is to evaluate the effectiveness of a previously developed storytelling intervention on anticoagulation (AC) initiation/persistence in African American and Black patients with atrial…
- Conditions
- Atrial Fibrillation, Atrial Flutter, Adherence, Medication, Anticoagulants and Bleeding Disorders
- Trial name
- NCT05997914
- Testing
- Storytelling Intervention
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Massachusetts, Worcester
Thrombosis
Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis
The objective of this trial is to demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis of thrombosis as an alternative to heparin-based anticoagulation.
- Trial name
- DESIR-ABLE (NCT00913133)
- Testing
- Desirudin
- Where
- 16 sites in United States
- Volunteers
- 516 people
- Sponsor
- Canyon Pharmaceuticals, Inc.
Post-Cardiac Surgery Patients
Value Analysis in Patients Undergoing Self-Management Training Using a Coagulometer
Prior research has not assessed the value of remote patient monitoring (RPM) systems for patients undergoing anticoagulation therapy after cardiac surgery.
- Trial name
- VAPUST (NCT06423521)
- Testing
- Standard of Care (SOC), Remote Patient Monitoring (RPM)
- Where
- Portugal
- Volunteers
- 28 people
- Sponsor
- Ana Rita Londral, PhD
LVAD (Left Ventricular Assist Device) Thrombosis
DOT HeartMate 3 Study
A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.
- Trial name
- NCT04974684
- Testing
- HeartMate 3, Apixaban
- Where
- Czechia
- Volunteers
- 45 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)
ImproveR International (BI-001-IM)
The objectives of this registry are to assess the use of the thrombin-specific anticoagulant bivalirudin during percutaneous coronary intervention (PCI) in a real life setting.
- Trial name
- NCT00290849
- Testing
- Bivalirudin
- Where
- Denmark
- Volunteers
- 4,000 people
- Sponsor
- Nycomed
Coronary Artery Disease, Percutaneous Coronary Intervention
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT + Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- NCT05638867
- Testing
- Aspirin + Clopidogrel + Rivaroxaban, Aspirin + Clopidogrel
- Where
- China
- Volunteers
- 3,944 people
- Sponsor
- China National Center for Cardiovascular Diseases
Significant Bleeding Risk
Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
To demonstrate that the efficacy of OCTAPLEX as a reversal agent in patients under Vitamin K Antagonist (VKA) therapy with the need for urgent surgery with significant bleeding risk is clinically non-inferior to that Beriplex®…
- Trial name
- NCT02740335
- Testing
- Octaplex, Beriplex P/N (Kcentra)
- Where
- 86 sites in United States, Belarus and 9 more
- Volunteers
- 208 people
- Sponsor
- Octapharma
Atrial Fibrillation, Venous Thromboembolism
NOACs Use in AF or VTE (SUNSHINE Registry)
The outcomes regiStry for non-vitamin k antagonist oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for better cliNical practicE (SUNSHINE) is a multicenter, prospective, observational non-interventional…
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Oral Anticoagulant
- Trial name
- NCT05378308
- Testing
- Patients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Henan Provincial People's Hospital
Healthy
Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects
This is a single-dose, randomized, double-blind, two-period, two-treatment, two-sequence, crossover, balanced, pharmacodynamic (PD) study with 7 days wash-out period.
- Trial name
- NCT05265676
- Testing
- Enoxaparin Sodium (Venus Remedies Limited), Enoxaparin Sodium (Sanofi)
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Venus Remedies Limited